HLUNAC Stock Overview

Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. More details

HLUNAC fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	1/6
Past Performance	4/6
Financial Health	5/6
Dividends	2/6

Rewards

Trading at 64.9% below our estimate of its fair value

Earnings are forecast to grow 9.84% per year

Earnings grew by 100.6% over the past year

Risk Analysis

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

H. Lundbeck A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for H. Lundbeck
Historical stock prices
Current Share Price	DKK 34.25
52 Week High	DKK 34.25
52 Week Low	DKK 23.95
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	9.42%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	4.42%

Recent updates

Shareholder Returns

	HLUNAC	GB Pharmaceuticals	GB Market
7D	0%	3.1%	0.6%
1Y	9.4%	-8.7%	3.4%

Return vs Industry: HLUNAC exceeded the UK Pharmaceuticals industry which returned -7.1% over the past year.

Return vs Market: HLUNAC exceeded the UK Market which returned -2.4% over the past year.

Price Volatility

Is HLUNAC's price volatile compared to industry and market?
HLUNAC volatility
HLUNAC Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.2%
Market Average Movement	5.9%
10% most volatile stocks in GB Market	11.5%
10% least volatile stocks in GB Market	3.4%

Stable Share Price: HLUNAC has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine HLUNAC's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1915	5,600	Deborah Dunsire	www.lundbeck.com

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer’s disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington’s disease, as well as other products.

H. Lundbeck A/S Fundamentals Summary

How do H. Lundbeck's earnings and revenue compare to its market cap?
HLUNAC fundamental statistics
Market cap	DKK 33.45b
Earnings (TTM)	DKK 2.48b
Revenue (TTM)	DKK 19.38b

12.3x

P/E Ratio

1.6x

P/S Ratio

Is HLUNAC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HLUNAC income statement (TTM)
Revenue	DKK 19.38b
Cost of Revenue	DKK 4.30b
Gross Profit	DKK 15.08b
Other Expenses	DKK 12.60b
Earnings	DKK 2.48b

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Nov 08, 2023

Earnings per share (EPS)	2.50
Gross Margin	77.79%
Net Profit Margin	12.79%
Debt/Equity Ratio	20.9%

How did HLUNAC perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

23%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/08/27 23:12
End of Day Share Price	2023/05/30 00:00
Earnings	2023/06/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

H. Lundbeck A/S is covered by 43 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Peter Ankersen	ABG Sundal Collier
Kamla Singh	AlphaValue

HLUNAC Stock Overview

Rewards

Risk Analysis

H. Lundbeck A/S Competitors

Hikma Pharmaceuticals

HUTCHMED (China)

Haleon

GSK

Price History & Performance

Recent News & Updates

H. Lundbeck A/S Raises Earnings Guidance for the Full Year 2025

H. Lundbeck to Share Pipeline Data and Key Insights into the Progression of Rare Disease, Multiple System Atrophy, at International MSA Congress in Boston

H. Lundbeck A/S to Present Positive Pipeline Data At American Academy of Neurology Annual Meeting

H. Lundbeck A/S Expands the Dose Findings to Intravenous Administration of Lu AG09222 in Migraine Prevention

H. Lundbeck A/S Approves to Distribute Dividend for the Year 2024

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S (Lundbeck) Approves Rxulti®? (Brexpiprazole) for the Treatment of Schizophrenia

Recent updates

H. Lundbeck A/S Raises Earnings Guidance for the Full Year 2025

H. Lundbeck to Share Pipeline Data and Key Insights into the Progression of Rare Disease, Multiple System Atrophy, at International MSA Congress in Boston

H. Lundbeck A/S to Present Positive Pipeline Data At American Academy of Neurology Annual Meeting

H. Lundbeck A/S Expands the Dose Findings to Intravenous Administration of Lu AG09222 in Migraine Prevention

H. Lundbeck A/S Approves to Distribute Dividend for the Year 2024

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S (Lundbeck) Approves Rxulti®? (Brexpiprazole) for the Treatment of Schizophrenia

H. Lundbeck A/S Provides Earnings Guidance for the Year 2025

H. Lundbeck A/S, Annual General Meeting, Mar 26, 2025

H. Lundbeck A/S Announces Board Changes

H. Lundbeck A/S Announces Positive Results from 12-Month Open-Label Extension of the PACIFIC Trial Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies

H. Lundbeck A/S (Lundbeck) Announces That the U.S. Food and Drug Administration Plans to Host A Psychopharmacologic Drugs Advisory Committee Meeting to Seek Input on Issues Related to the Supplemental New Drug Application for Brexpiprazole

H. Lundbeck A/S to Report First Half, 2025 Results on Aug 20, 2025

H. Lundbeck A/S Announces Positive Results from the Resolve Trial

H. Lundbeck Initiates a Phase III Trial with Amlenetug for the Treatment of Multiple System Atrophy

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

Less than half of directors are independent

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

Less than half of directors are independent

Full year 2022 earnings released

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

Less than half of directors are independent

Less than half of directors are independent

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S to Report Q1, 2023 Results on May 10, 2023

Shareholder Returns

Price Volatility

About the Company

H. Lundbeck A/S Fundamentals Summary

Earnings & Revenue

Dividends

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources